Analysis: Japan Drug System Encourages Moves Abroad
This article was originally published in PharmAsia News
Oncolys BioPharma's experience with getting its Telomelysin carcinostatic drug through the U.S. FDA process highlights the legal and bureaucratic red tape of Japan's process, according to an analysis. The firm's president noted the U.S. FDA even advises a drug maker on which tests will not be needed while Japan has in place hurdles too high for small ventures to scale. There have been recent signs of change in Japan, but its domestic market is likely to continue to lag as Japanese drug makers move testing and sales elsewhere. (Click here for more - a subscription may be necessary
You may also be interested in...
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.